•  
  •  
  •  
  •  

2026-04-11 23:34:26

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Everest Industries Concludes Phase I Land Sale in Coimbatore for ₹100.83 Crore
  • Shalby Hospitals' Krishna Unit Receives 5-Year Approval for Kidney Transplants
  • Fabtech Technologies Cleanrooms Ltd. Reports Strong Order Book of ₹199 Crore, Pipeline Grows to ₹482 Crore
  • Enviro Infra Engineers Limited Secures Mega Projects Worth ₹972 Crore in Maharashtra
  • Panacea Biotec Ltd receives LoA from CMSS

Keywords Selected:  USA

Research

  • 45% of Newbie traders claim that 'not knowing enough' is the primary reason for losses incurred in Futures & Options trading - Sharekhan's survey reveals
  • Domestic primary aluminium manufacturing entities are behind the curve in the transition to a greener future: ICRA
  • Campus Activewear - IPO - Strong Business Model, but Valuation is Stretched

Stock Report

  • 3i Infotech Inc., USA receives order worth Rs. 2.76 crores
  • 3i Infotech Inc., USA receives order worth approx. Rs. 1.63 crores
  • Glenmark Pharmaceuticals announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S.
  • Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
  • Sunita Tools Ltd forms Wholly Owned Subsidiary, Sunita Defence Inc, in Wyoming, USA
  • 3i Infotech Inc., USA receives order worth Rs. 2.21 crores
  • TCS launches Gemini Experience Center in the US to help accelerate AI-powered manufacturing
  • Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials
  • LT Foods Secures Major Relief in U.S. Countervailing Duty Review
  • Biocon obtains approval for weight management drug, Liraglutide, in the United States
  • Lupin announces the approval and launch of Brivaracetam Oral Solution in the United States
  • TCS and Rajarambapu Sahakari Bank Deepen Partnership, Integrate TCS BaNCS for Treasury to Enhance Operations
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial
  • AION-Tech Solutions and Bulgarian Company Theoremus AD Sign MoU to Advance Multimodal Urban Mobility in India
  • Aion-Tech Solutions Ltd enters into MoU with Theoremus AD
  • Powerhouse Engines Selects Ramco Systems to Transform Engine MRO Operations
  • Sathgen Therapeutics Division expands to the U.S. with Launch of Princeton Based Subsidiary
  • Fineotex Chemical Ltd announces Strategic Acquisition of a Leading U.S. Specialty Oilfield Chemicals Group
  • Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States
  • Godavari Biorefineries Inc forms subsidiary in USA
  • Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S.
  • Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
  • XTGlobal announces new client win for Circulus AP Automation Solution in the U.S. Construction Sector
  • Lupin Launches Authorized Generic Version of Ravicti® in the United States

Industry News

  • LiaPlus AI raises INR 2 Crore in Seed Round led by Inflection Point Ventures

Latest Post

  • Everest Industries Concludes Phase I Land Sale in Coimbatore for ₹100.83 Crore
  • Shalby Hospitals' Krishna Unit Receives 5-Year Approval for Kidney Transplants
  • Fabtech Technologies Cleanrooms Ltd. Reports Strong Order Book of ₹199 Crore, Pipeline Grows to ₹482 Crore
  • Enviro Infra Engineers Limited Secures Mega Projects Worth ₹972 Crore in Maharashtra
  • Panacea Biotec Ltd receives LoA from CMSS


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025